AZN.ST - AstraZeneca PLC

Stockholm - Stockholm Real Time Price. Currency in SEK
852.70
+5.80 (+0.68%)
At close: 5:29PM CEST
Stock chart is not supported by your current browser
Previous Close846.90
Open847.30
Bid853.70 x 0
Ask853.90 x 0
Day's Range843.30 - 859.50
52 Week Range640.30 - 904.90
Volume277,192
Avg. Volume357,825
Market Cap1.108T
Beta (3Y Monthly)0.82
PE Ratio (TTM)498.07
EPS (TTM)1.71
Earnings DateN/A
Forward Dividend & Yield26.44 (3.12%)
Ex-Dividend Date2019-08-08
1y Target Est93.83
  • Is There An Opportunity With AstraZeneca PLC's (LON:AZN) 31% Undervaluation?
    Simply Wall St.

    Is There An Opportunity With AstraZeneca PLC's (LON:AZN) 31% Undervaluation?

    Today we will run through one way of estimating the intrinsic value of AstraZeneca PLC (LON:AZN) by taking the...

  • U.S. FDA approves AstraZeneca diabetes drug for treating heart failure risk
    Reuters

    U.S. FDA approves AstraZeneca diabetes drug for treating heart failure risk

    Farxiga is the first of its class to be approved in the United States for this indication, Ruud Dobber, executive vice president of BioPharmaceuticals at AstraZeneca said. "This is promising news for the 30 million people living with type-2 diabetes in the United States, as heart failure is one of the earliest cardiovascular complications for them, before heart attack or stroke," Dobber said.

  • Investing.com

    NewsBreak: Astrazeneca's Diabetes Drug Farxiga Gets U.S. Approval

    Investing.com -- AstraZeneca (LON:AZN) said Monday its Farxiga drug for reducing the risk of heart failure in type-2 diabetes patients had been approved for use in the U.S. by the Food and Drug Administration.

  • Benzinga

    Benzinga's Bulls And Bears Of The Week: Beyond Meat, Netflix, Johnson & Johnson And More

    Benzinga has examined the prospects for many investor favorite stocks over the past week. Bullish calls included a second-tier telecom and a fast-casual restaurant leader. Bearish calls included beleaguered ...

  • Benzinga

    AstraZeneca Shares Trade Higher After FDA Grants Breast Cancer Drug Priority Review

    AstraZeneca plc (NYSE: AZN ) and partner DAIICHI SANKYO/S ADR (OTC: DSNKY ) announced positive news Thursday on their HER-2 targeting antibody drug conjugate, or ADC. This should come as a relief for the ...

  • Reuters

    UPDATE 1-AstraZeneca breast cancer treatment gets FDA priority review

    AstraZeneca Plc said on Thursday that the U.S. drug regulator will give a speedy review to its experimental breast cancer treatment, which could put the British drugmaker in direct competition with bigger rival Roche Holding AG. The U.S. Food and Drug Administration (FDA) accepted AstraZeneca's application and granted the treatment, trastuzumab deruxtecan, a priority review for the treatment of HER2-positive metastatic breast cancer, the drugmaker said.

  • AbbVie, Bristol-Myers Squibb Getting the Most From Workers
    GuruFocus.com

    AbbVie, Bristol-Myers Squibb Getting the Most From Workers

    Pharmaceutical companies that top the list in terms of sales per employee Continue reading...

  • ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology
    PR Newswire

    ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology

    LOS ANGELES , Oct. 14, 2019 /PRNewswire/ -- ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca ...

  • New Sanofi CEO Looks to Shake Things Up
    GuruFocus.com

    New Sanofi CEO Looks to Shake Things Up

    Paul Hudson is examining the organization from top to bottom with the goal of developing a strategy to put the company on the road to success Continue reading...

  • Hedge Funds Are Undecided About AstraZeneca plc  (AZN)
    Insider Monkey

    Hedge Funds Are Undecided About AstraZeneca plc (AZN)

    As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the second quarter. We get to see hedge funds' thoughts towards the market and […]

  • Bloomberg

    Trio Wins Nobel for Oxygen Studies That Led to Anemia Drugs

    (Bloomberg) -- Three researchers from the U.S. and Britain won a Nobel Prize for showing how cells sense and adapt to changing oxygen levels, a line of research that’s already led to the development of new drugs.Americans William Kaelin of the Dana-Farber Cancer Institute in Boston and Gregg Semenza of Baltimore’s Johns Hopkins Medicine, and Peter Ratcliffe of the Francis Crick Institute in London received this year’s award for physiology or medicine, the Nobel Assembly at the Karolinska Institute said Monday in a statement.“The seminal discoveries by this year’s Nobel laureates revealed the mechanism for one of life’s most essential adaptive processes,” the assembly said in the statement. “Their discoveries have also paved the way for promising new strategies to fight anemia, cancer and many other diseases.”Semenza and Ratcliffe separately studied the processes surrounding the sensing of oxygen, and found it was at work in virtually all the body’s tissues. Semenza worked in the 1990s on identifying a protein complex that binds to cells’ DNA in response to levels of oxygen in the environment.The complex, called hypoxia inducible factor, regulates production of red blood cells. The science behind it is the basis for an anemia drug codeveloped by AstraZeneca Plc and Fibrogen Inc. called roxadustat that was approved in China in December.Astra is just a few steps away from bringing the drug to patients, said Mene Pangalos, executive vice president of biopharmaceutical research and development, in an email. “This would never have been possible without early breakthroughs of this year’s Nobel winners,” he said.GlaxoSmithKline Plc has filed for Japanese approval of a drug based on the mechanism, called daprodustat. Kaelin’s work linked the same oxygen-regulating machinery to a role in cancer, which is also being mined for potential therapeutics.Annual prizes for achievements in physics, chemistry, medicine, peace and literature were established in the will of Alfred Nobel, the Swedish inventor of dynamite, who died in 1896. The total amount for each of the 2019 prizes is 9 million kronor ($909,000).(Updates with company comment in sixth paragraph)\--With assistance from John Lauerman.To contact the reporters on this story: Niklas Magnusson in Stockholm at nmagnusson1@bloomberg.net;Veronica Ek in Stockholm at vek@bloomberg.netTo contact the editors responsible for this story: Jonas Bergman at jbergman@bloomberg.net, ;Tasneem Hanfi Brögger at tbrogger@bloomberg.net, Eric PfannerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Reuters

    FDA green lights AstraZeneca's asthma drug Fasenra for self-administration

    British drugmaker AstraZeneca said on Friday that the U.S. Food and Drug Administration (FDA) has approved self-administration of its asthma treatment Fasenra which uses a pre-filled, single-use auto-injector pen. The move is a boost for the drugmaker's respiratory portfolio after the regulator earlier this week declined to approve AstraZeneca's combination therapy to treat smoker's lung, as it tries to catch up with domestic rival GlaxoSmithKline. "We can now offer Fasenra in an even more convenient way, giving U.S. healthcare providers and patients the option of administering Fasenra at home or in a doctor's office," Mene Pangalos, executive vice president of BioPharmaceuticals R&D said.

  • Viela Bio officially goes public
    American City Business Journals

    Viela Bio officially goes public

    Gaithersburg’s Viela Bio Inc. began publicly trading Thursday on the Nasdaq. The clinical-stage biotech is offering 7.9 million shares of common stock priced at $19 per share, positioning the company to raise roughly $150 million. Viela (NASDAQ: VIE) is also giving underwriters the option to buy up to an additional 1.19 million shares at the initial public offering price for 30 days.

  • Why this UC Berkeley gene therapy spinout is targeting a $100 million IPO
    American City Business Journals

    Why this UC Berkeley gene therapy spinout is targeting a $100 million IPO

    The Emeryville company says it has improved on the traditional way of delivering corrected copies of genes.

  • Brexit stockpiling shows up in manufacturing data and bakery results
    MarketWatch

    Brexit stockpiling shows up in manufacturing data and bakery results

    The extent of stockpiling ahead of a possible hard Brexit was on display in Tuesday in areas ranging from manufacturing data to a bakery’s results.

  • Does AstraZeneca's (LON:AZN) Share Price Gain of 66% Match Its Business Performance?
    Simply Wall St.

    Does AstraZeneca's (LON:AZN) Share Price Gain of 66% Match Its Business Performance?

    Stock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses...

  • Reuters

    UPDATE 2-Weak U.S., euro zone data push European shares lower

    European shares ended a three-day winning streak on Tuesday as investors were gripped by growth worries after poor U.S. manufacturing data fanned fears of slowing growth in the world's largest economy. The pan-European STOXX 600 index touched session lows, and closed down 1.3% after data showed U.S. manufacturing contracted for the second month in September, knocking U.S. stocks. This followed on from euro zone data that showed manufacturing activity contracting at its steepest rate in almost seven years.

  • Reuters

    AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm

    AstraZeneca Plc said on Tuesday it would sell the global commercial rights for its drug to treat acid reflux to German pharmaceutical company Cheplapharm Arzneimittel GmbH for as much as $276 million. Cheplapharm will pay AstraZeneca about $243 million for Losec, a proton pump inhibitor developed by the British drugmaker. The global commercial rights being sold to Cheplapharm, for Losec (omeprazole) and its associated brands, excludes rights in China, Japan, the United States and Mexico, AstraZeneca said.

  • Reuters

    UPDATE 1-AstraZeneca's combo lung disease therapy fails to win FDA approval

    The U.S. Food and Drug Administration declined to approve AstraZeneca Plc's combination therapy to treat smoker's lung, the drugmaker said on Tuesday. AstraZeneca said that it will work closely with the FDA regarding next steps, including submitting results from an additional late-stage study, which was not completed at the time the marketing application was submitted to the health regulator. The therapy, PT010, was approved in Japan in June as a triple-combination therapy to relieve symptoms of chronic obstructive pulmonary disease (COPD), AstraZeneca said.

  • Reuters

    AstraZeneca strengthens Lynparza push with prostate cancer data

    AstraZeneca presented results on Monday for a trial of its Lynparza drug against prostate cancer, which it hopes could lead to wider regulatory approval for the treatment for use against more forms of the disease. The British drugmaker, together with development partner Merck & Co, said Lynparza was shown to delay disease progression in an aggressive and difficult-to-treat type of prostate cancer by a median 3.8 months in the group most sensitive to the treatment. The data, presented at the annual conference of the European Society for Medical Oncology (ESMO) in Barcelona, adds to further promising results presented on Saturday at the conference that may lead to wider use in women suffering from ovarian cancer.

  • AstraZeneca, Merck ovarian cancer treatment improves progression-free survival
    Reuters

    AstraZeneca, Merck ovarian cancer treatment improves progression-free survival

    The study tested Lynparza in patients as an add-on to an already existing standard of care, bevacizumab, and was compared to a group of patients given bevacizumab alone. The treatment showed a statistically significant and clinically meaningful improvement in progression-free survival in women with newly diagnosed advanced ovarian cancer, the companies said. Lynparza added to bevacizumab reduced the risk of disease progression or death by 41% in the overall trial population.

  • Reuters

    UPDATE 1-AstraZeneca, Merck ovarian cancer treatment improves progression-free survival

    AstraZeneca Plc and Merck & Co Inc said on Monday their treatment for newly diagnosed advanced ovarian cancer improved progression-free survival in patients tested in a late-stage study. The study tested Lynparza in patients as an add-on to an already existing standard of care, bevacizumab, and was compared to a group of patients given bevacizumab alone. The treatment showed a statistically significant and clinically meaningful improvement in progression-free survival in women with newly diagnosed advanced ovarian cancer, the companies said.

  • Reuters

    AstraZeneca, Merck cancer treatment attains meaningful improvement in progression-free survival

    AstraZeneca Plc and Merck & Co Inc said on Monday their drug to treat a form of ovarian cancer improved progression-free survival in patients tested in a late-stage study. The study tested Lynparza in patients as an add-on to an already existing standard of care, bevacizumab, and was compared to a group of patients given bevacizumab alone. Lynparza added to bevacizumab reduced the risk of disease progression or death by 41% in the overall trial population.